421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors

Bibliographic Details
Main Authors: Anna Olsson-Brown, Joseph Sacco, Mark Middleton, Kevin Harrington, Robert Coffin, Howard Kaufman, Suzanne Thomas, Praveen Bommareddy, Francesca Aroldi, Pablo Nanclares, Lavita Menezes, Selda Samakoglu
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-ded3a2e10fe643758a8db510b6c2d64c
record_format Article
spelling doaj-ded3a2e10fe643758a8db510b6c2d64c2020-12-11T10:04:47ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0421421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumorsAnna Olsson-Brown0Joseph Sacco1Mark Middleton2Kevin Harrington3Robert Coffin4Howard Kaufman5Suzanne Thomas6Praveen Bommareddy7Francesca Aroldi8Pablo Nanclares9Lavita Menezes10Selda Samakoglu112University of Liverpool, Wirral, UK2University of Liverpool, Wirral, UK2Churchill Hospital, Oxford, UKAff11 grid.18886.3f0000000112714623The Institute of Cancer Research/The Royal Marsden Hospital London UK Aff14 grid.417886.40000 0001 0657 5612Amgen Woburn MA USA Aff15 grid.430387.b0000000419368796Rutgers Cancer Institute of New Jersey New Brunswick NJ USA Aff1 Replimune Inc 18 Commerce Way 01801 Woburn MA USA 10Replimune, Woburn, MA, USA1University of Oxford, Oxford, UK3The Institute of Cancer Research, London, UK4Replimune Inc., Woburn, MA, USA4Replimune Inc., Woburn, MA, USA
collection DOAJ
language English
format Article
sources DOAJ
author Anna Olsson-Brown
Joseph Sacco
Mark Middleton
Kevin Harrington
Robert Coffin
Howard Kaufman
Suzanne Thomas
Praveen Bommareddy
Francesca Aroldi
Pablo Nanclares
Lavita Menezes
Selda Samakoglu
spellingShingle Anna Olsson-Brown
Joseph Sacco
Mark Middleton
Kevin Harrington
Robert Coffin
Howard Kaufman
Suzanne Thomas
Praveen Bommareddy
Francesca Aroldi
Pablo Nanclares
Lavita Menezes
Selda Samakoglu
421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
Journal for ImmunoTherapy of Cancer
author_facet Anna Olsson-Brown
Joseph Sacco
Mark Middleton
Kevin Harrington
Robert Coffin
Howard Kaufman
Suzanne Thomas
Praveen Bommareddy
Francesca Aroldi
Pablo Nanclares
Lavita Menezes
Selda Samakoglu
author_sort Anna Olsson-Brown
title 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
title_short 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
title_full 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
title_fullStr 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
title_full_unstemmed 421 Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors
title_sort 421 initial results of a phase 1 trial of rp2, a first in class, enhanced potency, anti-ctla-4 antibody expressing, oncolytic hsv as single agent and combined with nivolumab in patients with solid tumors
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT annaolssonbrown 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT josephsacco 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT markmiddleton 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT kevinharrington 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT robertcoffin 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT howardkaufman 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT suzannethomas 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT praveenbommareddy 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT francescaaroldi 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT pablonanclares 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT lavitamenezes 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
AT seldasamakoglu 421initialresultsofaphase1trialofrp2afirstinclassenhancedpotencyantictla4antibodyexpressingoncolytichsvassingleagentandcombinedwithnivolumabinpatientswithsolidtumors
_version_ 1724386504447361024

Similar Items